AbbVie Bilan de santé

Santé financière contrôle des critères 3/6

AbbVie possède un total de capitaux propres de $6.8B et une dette totale de $70.9B, ce qui porte son ratio d'endettement à 1040%. Son actif total et son passif total sont $141.9B et de $135.1B. L'EBIT de AbbVie est $18.7B ce qui fait que son ratio de couverture des intérêts 9.8. Elle dispose de liquidités et de placements à court terme de $13.2B.

Informations clés

1,040.0%

Ratio d'endettement

US$70.94b

Dette

Ratio de couverture des intérêts	9.8x
Argent liquide	US$13.16b
Fonds propres	US$6.82b
Total du passif	US$135.12b
Total des actifs	US$141.94b

Mises à jour récentes de la santé financière

We Think AbbVie (NYSE:ABBV) Can Stay On Top Of Its Debt

Sep 06

Here's Why AbbVie (NYSE:ABBV) Can Manage Its Debt Responsibly

May 21

Recent updates

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de ABBV ( $33.8B ) ne couvrent pas ses passifs à court terme ( $41.9B ).

Passif à long terme: Les actifs à court terme de ABBV ( $33.8B ) ne couvrent pas ses passifs à long terme ( $93.2B ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: Le ratio dette nette/capitaux propres de ABBV ( 847.1% ) est considéré comme élevé.

Réduire la dette: ABBV avait des capitaux propres négatifs il y a 5 ans, mais ils sont désormais positifs et se sont donc améliorés.

Couverture de la dette: La dette de ABBV est bien couverte par le flux de trésorerie opérationnel ( 26.3% ).

Couverture des intérêts: Les paiements d'intérêts de ABBV sur sa dette sont bien couverts par l'EBIT ( 9.8 x couverture).

AbbVie Bilan de santé

Santé financière contrôle des critères 3/6

Informations clés

Mises à jour récentes de la santé financière

We Think AbbVie (NYSE:ABBV) Can Stay On Top Of Its Debt

Here's Why AbbVie (NYSE:ABBV) Can Manage Its Debt Responsibly

Recent updates

AbbVie Inc. Declares Quarterly Cash Dividend, Payable on February 14, 2025

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

AbbVie: 3 Positives From The Earnings Report

AbbVie Inc. (NYSE:ABBV) entered into an agreement to acquire Aliada Therapeutics, Inc. for $1.4 billion.

AbbVie: Strong Dividends But Humira Disappoints

U.S. FDA Approves AbbVie (Foscarbidopa and Foslevodopa) for Adults Living with Advanced Parkinson's Disease

Upcoming dividend of US$1.55 per share

Allergan Aesthetics Announces Availability of Juvederm Voluma Xc for Moderate to Severe Temple Hollowing

AbbVie Inc. to Report Q3, 2024 Results on Oct 30, 2024

AbbVie: Dividend Discount Model Suggests Large Valuation Risks

Abbvie Submits Biologics License Application to the FDA for Telisotuzumab Vedotin (Teliso-V) in Previously Treated Non-Small Cell Lung Cancer

Ripple Therapeutics Announces Collaboration and Option-to-License Agreement with AbbVie to Develop Next-Generation Therapies for Glaucoma Management

Second quarter dividend of US$1.55 announced

We Think AbbVie (NYSE:ABBV) Can Stay On Top Of Its Debt

AbbVie's VrayLAR®? (Cariprazine) Receives Positive Reimbursement Recommendation by Canada's Drug Agency for the Treatment of Schizophrenia

Why AbbVie Remains One Of My Favorite Dividend Growers

Abbvie Receives Second Indication Approval from European Commission for Tepkinly® (Epcoritamab) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

AbbVie Inc. Announces Ontario and Quebec Are First Provinces to Reimburse Subcutaneous Epkinly™ (Epcoritamab) for the Treatment of Diffuse Large B-Cell Lymphoma Under New Early Access Process

Executive Chairman recently sold US$12m worth of stock

Consensus EPS estimates fall by 10%

AbbVie Inc. (NYSE:ABBV) completed the acquisition of Cerevel Therapeutics Holdings, Inc. (NasdaqCM:CERE) from FMR LLC and others.

AbbVie: Growth Is Still A Better Choice

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

AbbVie Inc. Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

AbbVie's EPKINLY™ Receives First-Ever Time-Limited Reimbursement Recommendation by Canada's Drug Agency

Executive Chairman notifies of intention to sell stock

AbbVie Q2 2024 Earnings Preview: Post Gonzalez Era Can Begin On Positive Note

Abbvie Announces Appointment of Roopal Thakkar as Executive Vice President, Research & Development and Chief Scientific Officer

Upcoming dividend of US$1.55 per share

AbbVie Inc. to Report Q2, 2024 Results on Jul 25, 2024

AbbVie: A Hold Again (Rating Downgrade)

AbbVie Announces Board Changes

AbbVie Receives Positive CHMP Opinion for Epcoritamab (Tepkinly) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

Earnings Tell The Story For AbbVie Inc. (NYSE:ABBV)

AbbVie Inc. (NYSE:ABBV) acquired Celsius Therapeutics, Inc. for $250 million.

U.S. Food and Drug Administration Grants Second Approval for AbbVie's EPKINLY (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma

AbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa)

First quarter dividend of US$1.55 announced

AbbVie Inc. Declares Quarterly Cash Dividend, Payable on August 15, 2024

AbbVie Inc. Announces Board of Directors Changes

AbbVie: 5 Reasons That Make A Buy Case

AbbVie Inc. Announces Positive Topline Results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine (ELAHERE®) for High Folate Receptor-Alpha (FRa) Expressing Platinum-Sensitive Ovarian Cancer

AbbVie Advances Oncology Pipeline with Start of Multiple Myeloma Phase 3 Clinical Trial for Investigational Asset ABBV-383

AbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

Looking For Both Income And Growth? 4%-Yielding AbbVie Has You Covered

AbbVie Inc. (NYSE:ABBV) completed the acquisition of Landos Biopharma, Inc. (NasdaqCM:LABP) from a group of shareholders.

Here's Why AbbVie (NYSE:ABBV) Can Manage Its Debt Responsibly

Health Canada Approves QULIPTA (atogepant) for the Preventive Treatment of Chronic Migraine in Adults

Abbvie Inc. Announces Board Changes, Effective July 1, 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Découvrir des entreprises saines